GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Price-to-Free-Cash-Flow

Neurocrine Biosciences (Neurocrine Biosciences) Price-to-Free-Cash-Flow : 38.57 (As of Apr. 28, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Price-to-Free-Cash-Flow?

As of today (2024-04-28), Neurocrine Biosciences's share price is $135.99. Neurocrine Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.53. Hence, Neurocrine Biosciences's Price-to-Free-Cash-Flow Ratio for today is 38.57.

The historical rank and industry rank for Neurocrine Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

NBIX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 23.74   Med: 42.22   Max: 6147.5
Current: 38.57

During the past 13 years, Neurocrine Biosciences's highest Price-to-Free-Cash-Flow Ratio was 6147.50. The lowest was 23.74. And the median was 42.22.

NBIX's Price-to-Free-Cash-Flow is ranked worse than
66.8% of 494 companies
in the Drug Manufacturers industry
Industry Median: 21.8 vs NBIX: 38.57

Neurocrine Biosciences's Free Cash Flow per Share for the three months ended in Dec. 2023 was $1.16. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $3.53.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Neurocrine Biosciences was 9.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 33.50% per year.

During the past 13 years, Neurocrine Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 76.30% per year. The lowest was -193.00% per year. And the median was 10.80% per year.


Neurocrine Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Neurocrine Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Price-to-Free-Cash-Flow Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.78 43.08 35.77 36.58 36.80

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.58 42.30 34.10 29.83 36.80

Competitive Comparison of Neurocrine Biosciences's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Price-to-Free-Cash-Flow falls into.



Neurocrine Biosciences Price-to-Free-Cash-Flow Calculation

Neurocrine Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=135.99/3.526
=38.57

Neurocrine Biosciences's Share Price of today is $135.99.
Neurocrine Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Neurocrine Biosciences  (NAS:NBIX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Neurocrine Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080